Nuclear Medicine and Biology
Volume 34, Issue 3 , Pages 239-246 , April 2007

Characterization of optically resolved 9-fluoropropyl-dihydrotetrabenazine as a potential PET imaging agent targeting vesicular monoamine transporters

  • Mei-Ping Kung

      Affiliations

    • Department of Radiology, University of Pennsylvania, Philadelphia, PA 19104, USA
    • ,
  • Catherine Hou

      Affiliations

    • Department of Radiology, University of Pennsylvania, Philadelphia, PA 19104, USA
    • ,
  • Rajesh Goswami

      Affiliations

    • Department of Radiology, University of Pennsylvania, Philadelphia, PA 19104, USA
    • ,
  • Datta E. Ponde

      Affiliations

    • Department of Radiology, University of Pennsylvania, Philadelphia, PA 19104, USA
    • ,
  • Michael R. Kilbourn

      Affiliations

    • Department of Radiology, University of Michigan, Ann Arbor, MI 48109, USA
    • ,
  • Hank F. Kung

      Affiliations

    • Department of Radiology, University of Pennsylvania, Philadelphia, PA 19104, USA
    • Department of Pharmacology, University of Pennsylvania, Philadelphia, PA 19104, USA
    • Corresponding Author InformationCorresponding author. Department of Radiology, University of Pennsylvania, Philadelphia, PA 19104, USA. Tel.: +1 215 662 3096; fax: +1 215 349 5035.

Received 12 October 2006 ,Revised 13 December 2006 ,Accepted 25 December 2006.

References 

  1. Albin R, Koeppe R. Rapid loss of striatal VMAT2 binding associated with onset of Lewy body dementia. Mov Disord. 2006;21:287–288
  2. Kilbourn MR. In vivo radiotracers for vesicular neurotransmitter transporters. Nucl Med Biol. 1997;24:615–619
  3. Stoessl AJ, de la Fuente-Fernandez R. Dopamine receptors in Parkinson's disease: imaging studies. Adv Neurol. 2003;91:65–71
  4. Tatsch K. Can SPET imaging of dopamine uptake sites replace PET imaging in Parkinson's disease?. Eur J Nucl Med Mol Imaging. 2002;29:711–714
  5. Frey KA. Can SPET imaging of dopamine uptake sites replace PET imaging in Parkinson's disease?. Eur J Nucl Med Mol Imaging. 2002;29:715–717
  6. Guilloteau D, Chalon S. PET and SPECT exploration of central monoaminergic transporters for the development of new drugs and treatments in brain disorders. Curr Pharm Des. 2005;11:3237–3245
  7. Ravina B, Eidelberg D, Ahlskog JE, Albin RL, Brooks DJ, Carbon M, et al. The role of radiotracer imaging in Parkinson disease. Neurology. 2005;64:208–215
  8. Van Laere K, Casteels C, De Ceuninck L, Vanbilloen B, Maes A, Mortelmans L, et al. Dual-tracer dopamine transporter and perfusion SPECT in differential diagnosis of parkinsonism using template-based discriminant analysis. J Nucl Med. 2006;47:384–392
  9. Booij J, Habraken JB, Bergmans P, Tissingh G, Winogrodzka A, Wolters EC, et al. Imaging of dopamine transporters with iodine-123-FP-CIT SPECT in healthy controls and patients with Parkinson's disease. J Nucl Med. 1998;39:1879–1884
  10. Innis RB, Seibyl JP, Scanley BE, Laruelle M, Abi-Dargham A, Wallace E, et al. Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson disease. Proc Natl Acad Sci U S A. 1993;90:11965–11969
  11. Meegalla SK, Plössl K, Kung M-P, Stevenson DA, Mu M, Kushner S, et al. Specificity of diastereomers of [99mTc]TRODAT-1 as dopamine transporter imaging agents. J Med Chem. 1998;41:428–436
  12. Mozley PD, Schneider JS, Acton PD, Plössl K, Stern MB, Siderowf A, et al. Binding of [99mTc]TRODAT-1 to dopamine transporters in patients with parkinson's disease and in healthy volunteers. J Nucl Med. 2000;41:584–589
  13. Vander T, Borght M, Sima AA, Kilbourn MR, Desmond TJ, Kuhl DE, et al. [3H]Methoxytetrabenazine: a high specific activity ligand for estimating monoaminergic neuronal integrity. Neuroscience. 1995;68:955–962
  14. Kilbourn M, Frey K. Striatal concentrations of vesicular monoamine transporters are identical in MPTP-sensitive (C57BL/6) and -insensitive (CD-1) mouse strains. Eur J Pharmacol. 1996;307:227–232
  15. Kilbourn MR, Kuszpit K, Sherman P. Rapid and differential losses of in vivo dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) radioligand binding in MPTP-treated mice. Synapse. 2000;35:250–255
  16. Kilbourn MR, Frey KA, Vander Borght T, Sherman PS. Effects of dopaminergic drug treatments on in vivo radioligand binding to brain vesicular monoamine transporters. Nucl Med Biol. 1996;23:467–471
  17. Frey KA, Koeppe RA, Kilbourn MR. Imaging the vesicular monoamine transporter. Adv Neurol. 2001;86:237–247
  18. Bohnen NI, Albin RL, Koeppe RA, Wernette KA, Kilbourn MR, Minoshima S, et al. Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson disease. J Cereb Blood Flow Metab. 2006;26:1198–1212
  19. Lee CS, Schulzer M, de la Fuente-Fernandez R, Mak E, Kuramoto L, Sossi V, et al. Lack of regional selectivity during the progression of Parkinson disease: implications for pathogenesis. Arch Neurol. 2004;61:1920–1925
  20. Albin RL, Koeppe RA, Bohnen NI, Nichols TE, Meyer P, Wernette K, et al. Increased ventral striatal monoaminergic innervation in Tourette syndrome. Neurology. 2003;61:310–315
  21. Mehvar R, Jamali F, Watson MW, Skelton D. Pharmacokinetics of tetrabenazine and its major metabolite in man and rat. Bioavailability and dose dependency studies. Drug Metab Dispos. 1987;15:250–255
  22. Kilbourn MR, Lee LC, Heeg MJ, Jewett DM. Absolute configuration of (+)-alpha-dihydrotetrabenazine, an active metabolite of tetrabenazine. Chirality. 1997;9:59–62
  23. Kilbourn M, Sherman P. In vivo binding of (+)-[alpha]-[3H]dihydrotetrabenazine to the vesicular monoamine transporter of rat brain: bolus vs. equilibrium studies. Eur J Pharmacol. 1997;331:161–168
  24. Frey KA, Koeppe RA, Kilbourn MR, Vander Borght TM, Albin RL, Gilman S, et al. Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging. Ann Neurol. 1996;40:873–884
  25. Goswami R, Ponde DE, Kung MP, Hou C, Kilbourn MR, Kung HF. Fluoroalkyl derivatives of dihydrotetrabenazine as positron emission tomography imaging agents targeting vesicular monoamine transporters. Nucl Med Biol. 2006;33:685–694
  26. Kung M-P, Essman WD, Frederick D, Meegalla S, Goodman M, Mu M, et al. IPT: a novel iodinated ligand for the CNS dopamine transporter. Synapse. 1995;20:316–324
  27. Scherman D, Raisman R, Ploska A, Agid Y. [3H]Dihydrotetrabenazine, a new in vitro monoaminergic probe for human brain. J Neurochem. 1988;50:1131–1136
  28. Kilbourn M, Lee L, Borght TV, Jewett D, Frey K. Binding of [alpha]-dihydrotetrabenazine to the vesicular monoamine transporter is stereospecific. Eur J Pharmacol. 1995;278:249–252
  29. Schwarting RKW, Huston JP. The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments. Prog Neurobiol. 1996;50:275–331
  30. Masuo Y, Pelaprat D, Scherman D, Rostene W. [3H]Dihydrotetrabenazine, a new marker for the visualization of dopaminergic denervation in the rat striatum. Neurosci Lett. 1990;114:45–50

PII: S0969-8051(07)00002-9

doi: 10.1016/j.nucmedbio.2006.12.005

Nuclear Medicine and Biology
Volume 34, Issue 3 , Pages 239-246 , April 2007

Article Tools

* Image Usage & Resolution